Robert S. Siegel

George Washington University

Papers

3

Total Citations

12

H-Index

2

About

Dr. Robert S. Siegel is a leading oncologist whose research focuses on transforming the treatment landscape for head and neck cancers, particularly locally advanced oropharyngeal squamous cell carcinoma (OPSCC). His major contribution is pioneering a novel, de-escalation treatment strategy that combines induction chemotherapy with transoral robotic surgery (TORS), aiming to reduce the lifelong morbidity associated with standard chemoradiation. Through a series of phase II studies (2017–2019), he has demonstrated the efficacy of this approach, offering patients a definitive surgical option that may spare them from the severe side effects of radiation. While his most-cited papers have garnered modest citation counts (2–5 each), their clinical significance is profound, representing a paradigm shift toward functional preservation in OPSCC management. Dr. Siegel’s work is notable for its patient-centered focus, challenging established protocols and providing a viable alternative for those seeking to maintain quality of life after cancer treatment. His ongoing updates and retrospective reviews continue to refine this promising therapeutic pathway, marking him as an innovator in head and neck surgical oncology.

Research Focus

Key Achievements

2
H-Index
3
Papers
12
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Phase II study: Induction chemotherapy & transoral surgery as definitive tx for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—A novel approach.
5 citations · 2017
📈 Most Prolific Year: 2017 (1 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: George Washington University

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago